Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2003-06-20
2009-06-30
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S141100, C424S152100
Reexamination Certificate
active
07553488
ABSTRACT:
The present invention relates to compounds and methods for modulating, reducing or inhibiting, inflammatory reactions in a patient. Particularly, inflammatory reactions that are targeted by the present invention are cell migration, secretion of toxic products and proteolysis at a site of inflammation. Reduction of inflammation manifestations and reactions occurs by using an anti-S100 polynucleotide or polypeptide inhibitor or antagonist, which is essentially targeted against S100A8, S100A9 or S100A12, alone or in combination with other inhibitors of chemokines or immune modulating products.
REFERENCES:
patent: 5248825 (1993-09-01), Dinerstein et al.
patent: 5731166 (1998-03-01), Geczy et al.
patent: 6103497 (2000-08-01), Hillman et al.
patent: 6706683 (2004-03-01), Seto et al.
patent: 2002/0192228 (2002-12-01), Hanash
patent: 2005/0118688 (2005-06-01), Freeze et al.
patent: 2006/0281674 (2006-12-01), Tessier et al.
patent: 2007/0231317 (2007-10-01), Tessier et al.
patent: 0263072 (1988-04-01), None
patent: WO00/18970 (2000-04-01), None
Rouleau, P., et al. 2003 Clinical Immunology 107: 46-54.
Hessian, P.A., et al. 2001 Eur. J. Biochem. 268: 353-363.
Donato, Rosario: “Functional roles of S100 proteins, calclum-binding proteins of the EF-hand type” Biochimica et Biophysica Acta 1450 (1999), pp. 191-231.
Ravasi, Timothy et al.: “Probing the S100 protein family through genomic and functional analysis” Genomics 84 (2004), pp. 10-22.
Mauro Perretti et al., Mobilizing Lipocortin 1 in adherent human leukocytes downregulates their transmigration, Nat Medicine, 1996, 2: 1259-1262.
Eue et al., Transendothelial migration of 27E10+ human monocytes, International Immunology, 2000, vol. 12: 1593-1604.
Harrison et al., Oxidation Regulates the Inflammatory Properties of the Murine S100 Protein S100A8, The Journal of Biological Chemistry, 1999, vol. 274: 8561-8569.
Newton et al., The Human S100 Protein MRP-14 Is a Novel Activator of the β2 Integrin Mac-1 on Neutrophils, The Journal of Immunology, 1998, 160: 1427-1435.
Dunn C J et al: “Increased expression of neutrophil MRP8 and MRP14 is associated with vascular adhesion molecule activation and differential leukocyte infiltratioin in delayed-type hypersensitivity suggesting a proinflammatory role for S100 calcium-binding proteins” Biosis, XP002242712 abstract.
Yen Tina et al: “Induction of the S100 chemotactic protein, CP-10, in murine microvascular endothelial cells by proinflammatory stimuli”, Blood, W.B. Saunders, Philadelphia, VA, US, vol. 90, No. 12, Dec. 15, 1997, pp. 4812-4821.
Lagasse E et al: “Mouse MRP8 and MRP14, two intracellular calcium-binding proteins associated with the development of the myeloid lineage” Blood, W.B. Saunders, Philadelphia, VA, US, vol. 79, 1992, pp. 1907-1915.
Lackmann M.:“Identification of a chemotactic domain of the pro-inflammatory S100 Protein CP-10”, Journal of Immunology, The Williams and Wilkins Co. Baltimore, US, vol. 150, No. 7, Apr. 1, 1993, pp. 2981-2991.
Devery, Jannine M et al: “Acute inflammatory activity of the S100 protein CP-10: Activation of neutrophils in vivo and in vitro.” Journal of immunology, vol. 152, No. 4, 1994, pp. 1888-1897.
Ryckman Carle et al: “Proinflammatory activities of S100: Proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion.” Journal of Immunology, vol. 170, No. 6, Mar. 15, 2003, pp. 3233-3242.
Rouleau Pascal et al: The calcium-binding protein S100A12 induces neutrophil adhesion, migration, and release from bone marrow in mouse at concentrations similar to those found in human inflammatory arthritis., Clinical immunology (Orlando), vol. 107, No. 1, Apr. 20, 2003, pp. 46-54.
Geczy C., 1996, “Regulation and proinflammatory properties of the chemotactic protein, CP-10.”, Biochimica et Biophysica Acta, 1313: 246-252.
Odink K. et al., 1987, “Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis.”, Letters to Nature, vol. 330, pp. 80-82.
Ryckman C. et al., 2004, “Monosodium urate monohydrate crystals induce the release of the proinflammatory protein S100A8/A9 from neutrophils.”, Journal of Leukocyte Biology, vol. 76, pp. 433-440.
Frosch M. et al., 2000, “Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis.”, Arthritis & Rheumatism, vol. 43, No. 3, pp. 628-637.
Rouleau Pascal
Ryckman Carle
Tessier Philippe A.
Vandal Karen
Gambel Phillip
Ogilvy Renault LLP
Universite Laval
Wen Sharon
LandOfFree
Antibodies against S100A8 and S100A9 proteins for modulating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies against S100A8 and S100A9 proteins for modulating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies against S100A8 and S100A9 proteins for modulating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4054520